SCHEMBL1093086

SCHEMBL1093086

Nc1ccc(C=C(Cc2ccccc2)C(=O)O)cn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
GABRP O00591 2/20 0.47
GABRD O14764 2/20 0.47
GABRA1 P14867 2/20 0.47
GABRB1 P18505 2/20 0.47
GABRG2 P18507 2/20 0.47
GABRB3 P28472 2/20 0.47
GABRA5 P31644 2/20 0.47
GABRA3 P34903 2/20 0.47
GABRA2 P47869 2/20 0.47
GABRB2 P47870 2/20 0.47
GABRA4 P48169 2/20 0.47
GABRE P78334 2/20 0.47
GABRA6 Q16445 2/20 0.47
GABRG1 Q8N1C3 2/20 0.47
GABRG3 Q99928 2/20 0.47
GABRQ Q9UN88 2/20 0.47
TBXAS1 P24557 2/20 0.41
CES2 O00748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1093084 1.00 CYP3A4 (0.64) CYP3A4CYP2C9GABRPGABRDGABRA1
SCHEMBL1092838 0.85 CYP3A4 (0.68) CYP3A4CYP2C9GABRPGABRDGABRA1
SCHEMBL1092835 0.85 CYP3A4 (0.68) CYP3A4CYP2C9GABRPGABRDGABRA1
SCHEMBL2274215 0.82 CYP3A4 (0.64) CYP3A4CYP2C9TBXAS1CES2CES1
SCHEMBL2274219 0.82 CYP3A4 (0.64) CYP3A4CYP2C9TBXAS1CES2CES1
SCHEMBL2280955 0.79 CYP3A4 (0.59) CYP3A4CYP2C9TBXAS1CES2CES1
SCHEMBL2277729 0.79 CYP3A4 (0.59) CYP3A4CYP2C9TBXAS1NNMT
SCHEMBL2277727 0.79 CYP3A4 (0.59) CYP3A4CYP2C9TBXAS1NNMT
SCHEMBL2280959 0.79 CYP3A4 (0.59) CYP3A4CYP2C9TBXAS1CES2CES1
SCHEMBL58023 0.79 CYP3A4 (1.00) CYP3A4CYP2C9TBXAS1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153652-B2 Fab I inhibitors AFFINIUM PHARMACEUTICALS, INC. (CA) 2012-04-10 US disclosed
US-20120010127-A1 Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same BERMAN JUDD M (CA) 2012-01-12 US disclosed
US-20110190283-A1 Fab I Inhibitors DEBIOPHARM INTERNATIONAL SA (CH) 2011-08-04 US disclosed
US-20110098277-A1 Fab I Inhibitors DEBIOPHARM INTERNATIONAL SA (CH) 2011-04-28 US disclosed
US-7879872-B2 comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 AFFINIUM PHARMACEUTICALS, INC. (CA) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010127-A1 Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same DBI, SERPINB1, CTSF CYP3A4 4356/4885CYP2C9 4567/4885GABRP 4272/4885
US-20110098277-A1 Fab I Inhibitors SERPINB1, TMBIM6, GDI2 CYP3A4 3590/4885CYP2C9 3818/4885GABRP 623/4885
US-20110190283-A1 Fab I Inhibitors SERPINB1, TFPI, TFPI2 CYP3A4 2080/4885CYP2C9 1989/4885GABRP 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.